Velcade-Thalidomide-Dexamethasone Combination May Be Effective After A Stem Cell Transplant In Multiple Myeloma Patients – Results from a French study show that the combination of Velcade (bortezomib), thalidomide (Thalo­mid), and dexamethasone (Decadron), commonly referred to as VTD, may improve response rates in multiple myeloma patients after stem cell trans­planta­tion. The complete response rate for patients who received VTD as a consolidation therapy (52 percent) was significantly higher than the rate for patients who re­ceived a placebo (30 percent). The time to progression was also longer in patients who received VTD (62 percent), compared to those who re­ceived a placebo (29 percent). All patients had also received VTD as induction therapy prior to stem cell transplantation. For more information, please refer to the letter in the journal Leukemia (abstract).

Revlimid May Not Worsen Pre-Existing Peripheral Neuropathy In Relapsed Or Refractory Myeloma Patients – Results from an Italian study indicate that Revlimid (lenalidomide) does not worsen pre-existing peripheral neuropathy (pain, tingling, and loss of sensation in the extremities due to nerve damage) in relapsed and refractory multiple myeloma patients. The investigators administered Revlimid and dexa­metha­sone to 30 patients who had previously received Velcade or thalidomide. After 12 months of Revlimid therapy, peripheral neuropathy did not worsen in patients with pre-existing peripheral neuropathy and did not develop in any of the patients without pre-existing neuropathy. Based on these results, the investi­gators recommend longer follow-up studies to confirm Revlimid’s safety in patients with pre-existing peripheral neuropathy. For more information, please see the study in the Journal of the Peripheral Nervous System (abstract).

Heavy/Light Chain Assay May More Effectively Measure M-Protein Levels In Myeloma Patients – Findings from a European study indicate that the heavy/light chain (HLC) assay can be used as an effective prog­nostic test in patients with multiple myeloma. The investigators found that the HLC assay was better at identifying monoclonal (M) protein levels than other conventional tests, such as serum protein electro­phoresis and immuno­fixa­tion electro­phoresis. In addition, the investigators found that the HLC assay was not only more accurate, but could also detect subtle changes in patients with very low M-protein levels. The investigators note that results from the HLC assay and the free light chain (FLC) assay were generally in agreement, but both tests are needed to exclude the presence of residual disease. For more information, please refer to the study in Leukemia (subscription required).